Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Pass Below 200 Day Moving Average – Should You Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTPGet Free Report)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.42 and traded as low as $0.3566. Elite Pharmaceuticals shares last traded at $0.3599, with a volume of 451,833 shares changing hands.

Elite Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.44 and a current ratio of 7.34. The company’s 50 day moving average price is $0.36 and its 200 day moving average price is $0.42. The company has a market cap of $387.66 million, a price-to-earnings ratio of 12.00 and a beta of 0.38.

Elite Pharmaceuticals Company Profile

(Get Free Report)

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

See Also

Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.